Introduction

The translation of biomedical research into clinical practice is a complex and time-intensive process, often hindered by information overload and interdisciplinary communication barriers. Current methodologies predominantly rely on expert panels to manually synthesize literature, a process that can extend over several years. Large Language Models (LLMs) such as GPT-4o, with their advanced Natural Language Processing (NLP) capabilities and multimodal functions, provide a promising solution to this challenge [1]. This study aims to address three critical questions:

1. Can GPT-4o accurately extract actionable insights from heterogeneous research data?

2. How effectively can GPT-4o generate context-specific clinical protocols?

3. What safeguards are necessary to ensure ethical and reliable AI-driven protocol development?

Methods

Study design

This research employed a mixed-methods approach, integrating quantitative analyses of protocol alignment with qualitative evaluations of usability.

Data sources

The research corpus comprised 1,200 peer-reviewed articles (2018-2024) and 150 clinical trial reports sourced from PubMed, ClinicalTrials.gov, and institutional repositories. Clinical scenarios included 30 real-world cases across the following domains:

• Cardiology: Post-myocardial infarction management and arrhythmia treatment.

• Oncology: Adjuvant therapy for HER2-positive breast cancer.

• Neurology: Protocols for acute stroke interventions.

GPT-4o implementation

Inputs for GPT-4o included research texts, trial data, and clinical context (e.g., patient demographics, comorbidities). The tasks performed by GPT-4o included:

Summarizing key findings and grading the quality of evidence (e.g., GRADE criteria).

Generating draft protocols with step-by-step recommendations.

Adapting protocols to conform with institutional guidelines [2].

Evaluation metrics

Metrics for evaluation included:

• Accuracy: Alignment with gold-standard protocols determined by expert consensus.

• Efficiency: Time reduction achieved when compared to manual synthesis.

• Adaptability: Customization of protocols to suit local resources (e.g., low-income settings).

• Ethical compliance: Identification of potential biases or privacy risks.

Statistical analysis

Data were analyzed using descriptive statistics, Cohen’s kappa for inter-rater reliability, and regression models, employing SPSS version 28.0.

Results

Protocol generation accuracy

The overall alignment rate for GPT-4o was 89%, with 267 out of 300 protocol sections matching expert drafts. Performance varied by specialty, as shown in (Table 1).

Table 1: Performance varied by specialty.

Efficiency gains

GPT-4o reduced the time required for protocol drafting by 65%, decreasing from 40 hours to 14 hours per guideline. Additionally, it enabled the integration of new trial results into protocols within 2 hours, compared to the 2 weeks required for manual updates.

Adaptability and limitations

In resource-limited settings, GPT-4o successfully modified 80% of oncology protocols to align with the WHO Essential Medicines List [3]. However, ethical risks were identified in 15% of drafts, which contained ambiguous liability clauses regarding AI accountability for adverse outcomes.

Discussion

Strengths of GPT-4o

GPT-4o demonstrated robust capabilities in multimodal synthesis, effectively integrating text, tables, and trial figures to enhance protocol clarity (e.g., visual timelines for drug administration). It also exhibited dynamic learning by updating protocols using real-time alerts from PubMed, ensuring compliance with the latest evidence, and generating multilingual protocols (e.g., in Spanish and Mandarin) for global health initiatives.

Challenges and mitigations

Despite its strengths, GPT-4o faced challenges related to contextual nuances particularly with rare diseases (e.g., AL amyloidosis), attributed to limited training data. A proposed solution includes the development of hybrid human-AI workflows tailored for such niche conditions. Additionally, evidence of bias amplification was noted, particularly regarding gender disparities in cardiology trials. Strategies such as implementing bias-detection algorithms and diversity-aware training could help mitigate these issues [4].

Clinical implications

The standardization of protocols through GPT-4o has the potential to accelerate the adoption of evidence-based practices, particularly in low-resource hospitals. Furthermore, the protocols generated by GPT-4o can be utilized as training modules for resident education.

Conclusion

GPT-4o exhibits significant promise in transforming research findings into clinical action; however, its widespread integration necessitates rigorous validation and ethical oversight. Future initiatives should prioritize the establishment of real-time collaborative platforms where AI systems and healthcare professionals co-develop protocols, ensuring both innovation and patient safety.

Declarations

Ethics approval: This study utilized anonymized data and did not require institutional review board approval.

Conflicts of interest: The authors declare no competing interests.

References

1. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019; 25: 44-56.
2. Riely GJ, Wood DE, Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024; 22: 249-274.
3. Piggott T, Moja L, Huttner B, et al. WHO Model list of essential medicines: visions for the future. Bull World Health Organ. 2024; 102: 722-729.
4. Bellamy R K E, Dey K, Hind M, et al. AI Fairness 360: an extensible toolkit for detecting and mitigating algorithmic bias. IBM J Res Dev. 2019; 63: 1-1.